IP Library Granted Patent US 7,348,404
Granted Patent B2
US 7,348,404 · App. 11/455,388 · Granted Mar 25, 2008

Solid-phase peptide synthesis and agent for use in such synthesis

Assignee: Zealand Pharma A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,348,404
App. No.
11/455,388
Granted
Mar 25, 2008
Kind
B2
Abstract

The present invention relates to an improved process for the production of peptides by solid-phase synthesis. The invention also relates to agents which are useful in solid-phase peptide synthesis.

Claims (18)

1. A method of synthesizing a modified peptide having the following structure:

X-[target peptide]-[pre-sequence peptide]-Y,

wherein,

the pre-sequence peptide is a homooligomeric peptide sequence consisting of from about 3 to about 9 amino acid residues having a propensity factor P α >0.57 and a propensity factor P β ≦1.10,

the target peptide is a peptide having the structure:

-AA 1 -AA 2 ...........AA n -,

AA is an L or D amino acid residue,

X is hydrogen or an amino protective group,

Y is OH or NH 2 , and

n is an integer between 2 and 60;

said method comprising:

(a) coupling a pre-sequence peptide to a support, wherein said pre-sequence peptide comprises amino acid residues having side chain functionalities which are, if necessary, protected during the synthesis,

(b) coupling one or more N-α-protected amino acids to the N-terminus of the pre-sequence peptide to form said target peptide, wherein each coupling is performed in stepwise fashion and under conditions in which each of the amino acids of the target peptide is coupled and subsequently N-α-de-protected; wherein the pre-sequence peptide reduces or eliminates propensity of the peptide of interest to adopt a β-sheet structure during the coupling and increases the coupling efficiency during the synthesis of the target peptide in comparison to the synthesis of the target peptide prepared under the same conditions without said pre-sequence peptide; and

(c) cleaving said modified peptide from the support.

2. The method of claim 1 , wherein said pre-sequence peptide consists of from 5 to 7 amino acid residues.

3. The method of claim 1 , wherein said pre-sequence peptide consists of a polylysine.

4. The method of claim 3 , wherein said pre-sequence peptide consists of -(Lys) 6 -.

5. The method of claim 1 , wherein the yield or purity of said modified peptide is increased in comparison to the synthesis of the target peptide prepared under the same conditions without said pre-sequence peptide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2017
From: HOLM, ARNE; LARSEN, BJARNE DUE
To: ZEALAND PHARMACEUTICALS A/S
Reel/Frame 043051/0282 →
CHANGE OF NAME Recorded Jul 20, 2017
From: ZEALAND PHARMACEUTICALS A/S
To: ZEALAND PHARMA A/S
Reel/Frame 043266/0956 →
Priority Claims (1)
DK 0971/96 · Sep 19, 1996 · national
Continuity (3)
Continuation 0955133600 · Apr 18, 2000
Continuation In Part 0925452300
Related Publication 20070004905A1 · Jan 4, 2007